Square makes Tk 2,400 crore profit for first time

Square Pharmaceuticals, along with its associate entities, has made a profit of Tk 2,400 crore for the first time since its inception.

Based on the high profit in the 2024–25 fiscal year, the company declared a 120 percent cash dividend for its shareholders.

Year-on-year, profits of Square surged 13 percent to Tk 2,077 crore in FY25, while its sales advanced around 9 percent to Tk 7,628 crore, according to the company's financial reports.

This year, its profits from associates surged 23 percent to around Tk 320 crore, which helped Square Pharma's overall profit to rise 15 percent year-on-year to Tk 2,397 crore in the recently ended fiscal year.

Although its administrative costs grew at a slower pace compared to sales growth, its selling and distribution costs rose at a higher pace.

However, its finance costs dropped in the last fiscal year.

Due to a higher return on its investments, Square Pharma's income from investments surged by around 34 percent to Tk 620 crore, which boosted its net profit.

Its earnings per share stood at Tk 27.04 last year, up from Tk 23.61 in the previous year.

However, the lone pharma segment of the company saw lower sales and profits this year, as its sales slightly dropped to Tk 5,997 crore from the previous year's Tk 5,979 crore.

In the same period, its profits fell 5 percent to Tk 1,473 crore, the data shows.